91 related articles for article (PubMed ID: 17535083)
1. Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy.
Bachmann W; Petzinna D; Raptis SA; Wascher T; Westermeier T;
Clin Drug Investig; 2003; 23(10):679-86. PubMed ID: 17535083
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus.
Segal P; Eliahou HE; Petzinna D; Neuser D; Brückner A; Spengler M
Clin Drug Investig; 2005; 25(9):589-95. PubMed ID: 17532703
[TBL] [Abstract][Full Text] [Related]
5. Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial.
van de Laar FA; Lucassen PL; Kemp J; van de Lisdonk EH; van Weel C; Rutten GE
Diabetes Res Clin Pract; 2004 Jan; 63(1):57-65. PubMed ID: 14693413
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R
Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286
[TBL] [Abstract][Full Text] [Related]
8. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
9. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China.
Pan CY; Landen H
Clin Drug Investig; 2007; 27(6):397-405. PubMed ID: 17506590
[TBL] [Abstract][Full Text] [Related]
10. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.
Schnell O; Mertes G; Standl E;
Diabetes Obes Metab; 2007 Nov; 9(6):853-8. PubMed ID: 17924867
[TBL] [Abstract][Full Text] [Related]
11. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia.
Rosak C; Haupt E; Walter T; Werner J
Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
13. Effect of add-on acarbose to insulin therapy in routine clinical practice.
Klocke KR; Stauch K; Landen H
Clin Drug Investig; 2003; 23(10):621-7. PubMed ID: 17535077
[TBL] [Abstract][Full Text] [Related]
14. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
15. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
16. The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes.
Hermanns N; Burkert A; Haak T
Exp Clin Endocrinol Diabetes; 2004 Jun; 112(6):310-4. PubMed ID: 15216448
[TBL] [Abstract][Full Text] [Related]
17. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
18. Use of acarbose for eliminating the interval between meal consumption and insulin injection in patients with Type 1 diabetes.
Koch HH; Wudy A; Eberlein G; Quast C
Diabetes Nutr Metab; 1999 Jun; 12(3):195-201. PubMed ID: 10554902
[TBL] [Abstract][Full Text] [Related]
19. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
Domke A; Willms B
Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
